Correlation Between Gracell Biotechnologies and Viridian Therapeutics

Can any of the company-specific risk be diversified away by investing in both Gracell Biotechnologies and Viridian Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Gracell Biotechnologies and Viridian Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Gracell Biotechnologies and Viridian Therapeutics, you can compare the effects of market volatilities on Gracell Biotechnologies and Viridian Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Gracell Biotechnologies with a short position of Viridian Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Gracell Biotechnologies and Viridian Therapeutics.

Diversification Opportunities for Gracell Biotechnologies and Viridian Therapeutics

0.53

Correlation Coefficient

Gracell Biotechnologies  Viridian Therapeutics

Very weak diversification

The 3 months correlation between Gracell and Viridian is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Gracell Biotechnologies and Viridian Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viridian Therapeutics and Gracell Biotechnologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Gracell Biotechnologies are associated (or correlated) with Viridian Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viridian Therapeutics has no effect on the direction of Gracell Biotechnologies i.e., Gracell Biotechnologies and Viridian Therapeutics go up and down completely randomly.

Pair Corralation between Gracell Biotechnologies and Viridian Therapeutics

If you would invest  1,447  in Viridian Therapeutics on August 31, 2024 and sell it today you would earn a total of  740.00  from holding Viridian Therapeutics or generate 51.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	1.59%
Values	Daily Returns

Gracell Biotechnologies  vs.  Viridian Therapeutics

Gracell Biotechnologies

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Gracell Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Gracell Biotechnologies is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.

Viridian Therapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting fundamental indicators, Viridian Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Gracell Biotechnologies and Viridian Therapeutics

The main advantage of trading using opposite Gracell Biotechnologies and Viridian Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Gracell Biotechnologies position performs unexpectedly, Viridian Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will offset losses from the drop in Viridian Therapeutics' long position.

The idea behind Gracell Biotechnologies and Viridian Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.